Biologics and Immunomodulators for Immunobullous Diseases
At ODAC 2023, we had the opportunity to learn about the latest in treatments for blistering diseases from Dr. Karl Saardi, Associate Professor and Director of Inpatient Dermatology at George Washington University. We focused on the pemphigus and pemphigoid group of diseases, which we will review and summarize here.
Pemphigus
The pemphigus group of diseases is characterized by intraepidermal auto …
At ODAC 2023, we had the opportunity to learn about the latest in treatments for blistering diseases from Dr. Karl Saardi, Associate Professor and Director of Inpatient Dermatology at George Washington University. We focused on the pemphigus and pemphigoid group of diseases, which we will review and summarize here.
Pemphigus
The pemphigus group of diseases is characterized by intraepidermal auto … Continue reading "Biologics and Immunomodulators for Immunobullous Diseases"
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Andrew Alexis, co-chair of Skin of Color Update, and vice-chair for diversity and inclusion for the Weill Cornell Medical College Department of Dermatology. Dr. Alexis shares his take on how to address issues of mistrust that may impede clinical trial recruitment in diverse patient populations. Watch as he details why i … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Hadar Lev-Tov, associate professor of clinical dermatology and cutaneous surgery at the University of Miami Miller School of Medicine. Watch as Dr. Lev-Tov shares some of the treatments that are emerging in wound healing. Find out why a beta blocker may be the most well-kept secret in he … 
There are many procedural treatments that we have worked on finessing in dermatology, but for some patients with non-melanoma skin cancer, nonsurgical treatments should be discussed. We had the opportunity to review the strengths and weaknesses of nonsurgical treatment approaches for non-melanoma skin cancer and review the indications and future implications of these treatments at ODAC 2023 with D … 
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other … 